Association between triglyceride glucose combined with body mass index and hypertension in the NHANES 2017 to 2020

Association between triglyceride glucose combined with body mass index and hypertension in the NHANES 2017 to 2020

Introduction

Hypertension (HTN) is a major cause of the increasing economic burden of disease and mortality globally, with approximately 30% of adults worldwide currently suffering from HTN and 50–60% of adults in pre-hypertension1,2. The existence of a large number of pre-hypertension individuals indicates that the incidence of HTN will continue to increase in the future3. In addition, during HTN, peripheral arterial pressure increases, heart load increases, and vascular endothelial damage occurs, leading to damage to multiple target organs including the heart, brain, and kidneys. Therefore, prevention and management of HTN is a major challenge in global public health care.

Insulin resistance (IR) is closely related to the occurrence of HTN4,5. IR can lead to increased secretion of Ang II (Angiotensin II, Ang II) and aldosterone, excessive activation of the sympathetic nervous system, and promotion of oxidative stress, leading to HTN6,7,8,9. However, the “gold standard” of assessing IR, the high insulin-normal glucose clamp (HIEC), is an invasive technique that is complex, time-consuming, and expensive, and therefore not suitable for large-scale studies. Homeostasis model assessment (HOMA-IR) is an alternative metric to assess IR and has been shown to strongly correlate with HIEC, but it is also not suitable for large-scale clinical investigations due to the need to assess insulin levels and the high variability of HOMA-IR threshold levels. For the past few years, the triglyceride glucose (TyG) index and related parameters [Triglyceride glucose-Waist Circumference (TyG-WC), TyG-BMI] have become new alternative indicators for evaluating IR, characterized by simplicity, ease of operation, and low-cost, making it suitable for large-scale clinical screening. The existing research has confirmed that TyG is associated with the incidence rate of many diseases in combination with WC, waist hip ratio (WHR) and waist height ratio (WHtR)10. Among them, TyG-BMI is most closely related to HOMA-IR11,12,13,14,15. IR and obesity are closely related to the risk of hypertension. The correlation between TyG-BMI as a surrogate marker of IR and hypertension in the American population is still unclear. TyG-BMI is a composite index composed of fasting blood tests [triglycerides (TG), fasting blood glucose (FPG)] and body mass index (BMI), which can identify early IR risk and have broad clinical value16.

Although the high correlation between IR and HTN has been widely recognized, traditional IR evaluation methods are complex and not suitable for large-scale clinical investigations. Some studies have shown that TyG-BMI can be used as a substitute indicator for IR, but the relationship between TyG-BMI and HTN is not yet fully studied. Therefore, this study aims to validate the correlation between TyG-BMI and HTN in the American population using data from the NHANES database, providing a basis for the clinical application of TyG-BMI.

Materials and methods

Study design and population

The National Health and Nutrition Examination Survey (NHANES) is a nationally representative study conducted by the National Center for Health Statistics (NCHS) to assess the health and nutritional status of Americans. This research was performed by trained healthcare professionals. They investigated and collected data on demographics, diet, examinations, and laboratory findings to estimate the prevalence of major diseases and their associated risk factors. For specific information about the database, please visit the NHANES official website at https://www.cdc.gov/nchs/nhanes/. The NHANES study has obtained approval from the Ethics Review Committee of the National Health and Nutrition Examination Survey (NHCS), and all participants have filled out the written informed consent form. We selected NHANES data from 2017 to 2020 to analyze the association between the TyG-BMI and HTN. Exclusion criteria were (1) individuals aged < 20 years, (2) missing any of the metrics used to calculate the TyG-BMI [TG, FPG, height, weight), and (3) individuals with incomplete information on covariates.

Measurement of the TyG-BMI

The TyG-BMI was the exposure factor and was calculated by the following equation16: TyG-BMI = TyG × BMI, where TyG = Ln[TG (mg/dL) × FPG (mg/dL)/2]17, and BMI = weight (kg)/height (m2). TG was determined using the Wahlefeld method, and FPG was determined by enzymatic methods.

Definition of HTN

We determined whether participants have HTN based on their answers to the questionnaire, “Has your doctor told you that you have high blood pressure?” If the participants answered “yes” they were included in the group with HTN. The NHANES database diagnoses whether a patient has hypertension based on “The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report”18.

Measurement of covariates

Covariates include demographic information [age, race, education level, marital status, ratio of family income to poverty (PIR)], body measurement indicators [waist circumference (WC)], smoking status, drinking status, physical activity (PA), diabetes, and laboratory measurement indicators include total cholesterol (TC), High-density lipoprotein cholesterol (HDL-C), Low-density lipoprotein cholesterol (LDL-C). According to the smoking status of participants, they are classified as “current smokers”, “former smokers”, or “never smokers”. According to the Substance Abuse and Mental Health Services Administration (SAMHSA) guidelines19, drinking status was divided into three categories: never drinking (0 g/ day), moderate drinking (< 70 g/ day for men and < 56 g/ day for women), and excessive drinking (≥ 70 g/ day for men and ≥ 56 g/ day for women). According to the 2020 World Health Organization (WHO) Physical Activity and Sedentary Behavior Guidelines20, PA is divided into two categories: participants who engage in high-intensity activities for more than 75 min per week or moderate-intensity activities for more than 150 min per week are considered to have an active aerobic PA level, otherwise they are considered inactive. Diabetes status was determined by the participant’s answer to the question, “Has your doctor ever told you that you have diabetes?“, with a “yes” response being included as having diabetes. For a detailed explanation of the methods used to measure laboratory indicators such as blood lipids and glucose, please refer to the Laboratory Data Methods section on the NHANES website. (https://www.cdc.gov/nchs/data/nhanes/nhanes_99_00/lab13_met_lipids.pdf, https://www.cdc.gov/nchs/data/nhanes/nhanes_99_00/lab10am_met_plasma_glucose.pdf)

Statistical analysis

Continuous variables of a normal distribution were represented by mean ± standard deviation (SD), while skewed distributed variables were represented by interquartile range (IQR). Categorical variables were represented by frequency (%). When comparing baseline characteristics between groups with and without HTN, we use one-way analysis of variance (ANOVA) for normally distributed data, the Kruskal-Wallis H test for skewed distributed data, and chi-square test for categorical variables.

We used a multivariable logistic regression model (odds ratio [OR] and 95% confidence interval [CI]) to evaluate the association between TyG-BMI and HTN. Model 1 adjusted for age, gender, and race, while Model 2 further adjusted for demographic factors (including age, gender, race, education level, marital status, PIR), WC, smoking, alcohol consumption, and physical activity. Model 3 fully adjusted for all covariates. Additionally, we employed a smooth curve fitting to assess the linear relationship between TyG-BMI and HTN. Subgroups were divided by age, gender, race, education level, smoking status, PA, and diabetes, respectively. We analyzed subgroups using multiple logistic regression models and analyzed the significance of interactions between subgroups through likelihood ratio tests. Statistical analysis software included R 3.3.2 (http://www.R-project.org, the R Foundation) and Free Statistics 1.8. A bilateral P-value < 0.05 is considered statistically significant for differences.

Results

Study population

A total of 15,560 participants took part in the NHANES survey during 2017–2020. We excluded 6,328 participants under the age of 20, 5,298 participants who lacked complete information on the calculated TyG-BMI, and 865 individuals with incomplete covariate information. Finally, 3,069 individuals over the age of 20 with complete variable information were included in the study. The crowd screening process diagram is shown in Fig. 1.

Fig. 1
Association between triglyceride glucose combined with body mass index and hypertension in the NHANES 2017 to 2020

Flowchart of study population screening.

Full size image

Basic characteristics of the research population

The basic characteristics of the study population are shown in Table 1, the mean age of 3,069 participants was 50.0 ± 17.2 years, of which 48.8% were male. They were categorized into two groups based on whether they had HTN or not. Compared with the non-hypertensive population, those with hypertension had a higher average age (59.0 ± 14.2 vs. 45.2 ± 16.7), higher divorce rate (30.2% vs. 16.6%), and lower level of education (55.9% vs. 61.6%). And the percentage of Non-Hispanic blacks was higher (31.7% vs. 20.4%). In terms of lifestyle habits, the high blood pressure group smoked more (49.7% vs. 39.9%), fewer drinkers (63.7% vs. 73.9%), and fewer regular exercisers (51.5% vs. 62.4%). In terms of disease and physical and chemical indexes, hypertensive population had higher prevalence of BMI, WC, LDL-C, FPG and diabetes, and these differences were statistically significant (P < 0.05), while there were no statistically significant differences in gender, PIR, TC, and HDL-C between the two groups (P > 0.05).

Table 1 Baseline characteristic of participants.
Full size table

Correlation between TyG-BMI and HTN

One-way logistic regression analysis shows that age, race, education level, marital status, BMI, WC, TG, LDL-C, smoking status, drinking status, PA, and diabetes may be related to HTN (Table 2).

Table 2 Results of univariate analysis of hypertension.
Full size table

Multifactorial logistic regression analysis found that TyG-BMI was positively associated with HTN after the complete adjustment of covariates. When TyG-BMI was represented as a continuous variable, for every 10-unit increase in the TyG-BMI in the fully adjusted variable (Model 3), the risk of HTN increased by 4.3% (95% CI: 1.007–1.08, P = 0.018). When TyG-BMI was used as the Quartile, after full adjustment (model 3), there was still a positive association between the TyG-BMI and the increased risk of HTN. Compared with the smallest Quartile Q1 (≤ 205.44), the fully adjusted OR values of Q2 (205.49–244.86), Q3 (244.88–293.43), and Q4 (≥ 293.57) are 1.442 (95% CI: 1.074–1.935, P = 0.015), 2.069 (95% CI: 1.447–2.962, P < 0.001), 2.347 (95% CI: 1.427–3.859, P < 0.0002), respectively, each model has statistical significance (Table 3).

Table 3 Multivariate regression analysis of TyG-BMI and hypertension.
Full size table

In addition, the smoothed curve fitting analysis (Fig. 2) showed a nonlinear relationship between TyG-BMI and HTN (P = 0.016) after adjustment for all covariates(including age, race, education level, marital status, the ratio of family income to poverty, waist circumference, smoking, drinking, physical activity, diabetes, and TC, HDL-C, LDL-C). We further conducted an inflection point analysis on the curve (Table 4) and found that when the TyG-BMI is less than 242.192, every 1 increase in TyG-BMI value increases the risk of HTN by 1.1%. When the TyG-BMI was greater than 242.192, the increase in the risk of HTN with increasing TyG-BMI was not statistically significant (P > 0.05).

Fig. 2
figure b

Relationship between TyG-BMI and HTN. The solid red line representing the predicted value and the dashed area representing the 95% confidence interval.

Full size image
Table 4 Analysis of inflection points.
Full size table

Subgroup analysis

To test the robustness of the results, we conducted multiple logistic regression analyses after stratification by age, gender, race, education level, smoking status, physical activity, and diabetes status. After fully adjusting for covariates other than stratified variables, we found that the positive association between TyG-BMI and HTN remained stable among all subgroups except the age group. After age stratification, significant interactions were observed (P for interaction < 0.05), indicating that the correlation between TyG-BMI and HTN was more significant when the age was greater than 60 years old (Fig. 3).

Fig. 3
figure c

The forest plot of the subgroup analysis of TyG-BMI and HTN.

Full size image

Discussion

Through cross-sectional analysis of 3,069 adults in the NHANES database from 2017 to 2020, we found that the TyG-BMI is positively correlated with the presence of HTN with self-reported diagnosis, and the relationship remains robust after fully adjusted (Table 3). We explored the inflection point for the association of TyG-BMI with hypertension. However, the clinical significance and reliability of this critical value need further verification (Fig. 2). The results of subgroup analysis showed significant interaction after age stratification, and there is no significant difference in the correlation between TyG-BMI and HTN risk among other subgroups (gender, race, education level, smoking status, physical activity, and diabetes status).

Our finding suggested a significant correlation between TyG-BMI and the incidence of HTN in adults over 20 years in the United States, which is consistent with previous findings in Asian populations such as China, Japan, and Thailand20,21,22. Our finding suggests that TyG-BMI, as an easily accessible indicator, has a stable association with the occurrence of HTN in different ethnic groups. Although studies in both Asian and American populations have found a positive correlation between TyG-BMI and the prevalence of HTN, the significance of the association at different ages is somewhat controversial. A sub-analysis of a cross-sectional study on Chinese adults showed no significant difference in TyG-BMI among different age subgroups24. Another subgroup analysis of East Asian populations, including China and Japan, found that TyG-BMI was more significantly correlated with HTN in middle-aged adults25, whereas a subgroup analysis of a Japanese population with normal blood glucose found that the association was more pronounced in young individuals21. Our subgroup analysis showed a more significant association between TyG-BMI and HTN in the US population aged 60 years or older, probably due to cellular senescence, mitochondrial dysfunction, susceptibility to metabolic disorders and weakened self-regulatory ability in the elderly26,27, so that older adults with high TyG-BMI are more susceptible to abnormalities of glucose-lipid metabolism and induced HTN. The controversy surrounding the association between age and TyG BMI and hypertension in different study populations may be related to dietary and lifestyle habits in different regions, and further research can be conducted on this issue in the future.

The mechanism of TyG-BMI and HTN association remains unclear. Studies have shown that HTN is strongly related to impaired fasting glucose28and abnormal glucose tolerance29, and most patients with HTN are accompanied by metabolic system disorders30, among which IR and obesity are closely related to increased risk of blood pressure31,32. IR promotes abnormal activation of the Renin-Angiotensin-Aldosterone System (RAAS) and the Sympathetic Nervous System (SNS). Increased secretion of Ang II and aldosterone leads to constriction of small arteries throughout the body and increased vascular resistance, which promotes reabsorption of water and sodium by renal tubules, leading to an increase in blood volume and elevated blood pressure33. In addition, IR down-regulates nitric oxide synthesis, exacerbates vascular and systemic inflammation, and leads to vascular endothelial dysfunction, which also induces HTN34-36. What’s more, previous studies have shown a significant interaction between BMI, one of the commonly used indicators of obesity, and the risk of HTN3738,. Obesity not only exacerbates insulin resistance, but also produces reactive oxygen species (ROS) and a variety of inflammatory factors, including IL-1 and IL-6, which aggravate vascular damage and endothelial dysfunction, ultimately leading to HTN39. Therefore, monitoring TyG-BMI may be a clue to the presence of hypertension.

This study examined whether there is a correlation between TyG-BMI and HTN in the US population, having a diverse population base, and adjusting for major lifestyle factors. However, this study also has certain limitations. Firstly, cross-sectional studies can only analyze associations and cannot establish causal inferences. Secondly, we cannot exclude the residual confounding effects of unmeasured and unknown factors. Additionally, since blood pressure values on different days were not measured in the database, we did not use blood pressure values as the basis for diagnosing HTN. Instead, we used the doctor’s diagnosis results to determine whether patients had HTN, which may have led to bias in some hypertensive patients who did not seek medical treatment. We cannot determine whether patients have been diagnosed with hypertension based on their real-time blood pressure measurements, nor can we ascertain their treatment status or the effectiveness of their blood pressure control. Therefore, we are unable to exclude the potential impact of treatment on various measured indicators, and we cannot conduct subgroup analyses based on blood pressure categories. This limitation may introduce certain biases into our study. Therefore, more rigorous prospective cohort studies or randomized controlled trials are needed in the future to determine the causal relationship between the TyG-BMI and HTN and minimize the interference of confounding factors to further validate the reliability of the results of this study.

Conclusion

In conclusion, our finding suggested that TyG-BMI is positively associated with the risk of HTN in Americans aged 20 years or older, and this association is more pronounced in those aged 60 years or older. Thus, early monitoring of TyG-BMI may reduce the risk of HTN in the elderly population, thereby reducing the global healthcare burden.

Related Articles

Energy metabolism in health and diseases

Energy metabolism is indispensable for sustaining physiological functions in living organisms and assumes a pivotal role across physiological and pathological conditions. This review provides an extensive overview of advancements in energy metabolism research, elucidating critical pathways such as glycolysis, oxidative phosphorylation, fatty acid metabolism, and amino acid metabolism, along with their intricate regulatory mechanisms. The homeostatic balance of these processes is crucial; however, in pathological states such as neurodegenerative diseases, autoimmune disorders, and cancer, extensive metabolic reprogramming occurs, resulting in impaired glucose metabolism and mitochondrial dysfunction, which accelerate disease progression. Recent investigations into key regulatory pathways, including mechanistic target of rapamycin, sirtuins, and adenosine monophosphate-activated protein kinase, have considerably deepened our understanding of metabolic dysregulation and opened new avenues for therapeutic innovation. Emerging technologies, such as fluorescent probes, nano-biomaterials, and metabolomic analyses, promise substantial improvements in diagnostic precision. This review critically examines recent advancements and ongoing challenges in metabolism research, emphasizing its potential for precision diagnostics and personalized therapeutic interventions. Future studies should prioritize unraveling the regulatory mechanisms of energy metabolism and the dynamics of intercellular energy interactions. Integrating cutting-edge gene-editing technologies and multi-omics approaches, the development of multi-target pharmaceuticals in synergy with existing therapies such as immunotherapy and dietary interventions could enhance therapeutic efficacy. Personalized metabolic analysis is indispensable for crafting tailored treatment protocols, ultimately providing more accurate medical solutions for patients. This review aims to deepen the understanding and improve the application of energy metabolism to drive innovative diagnostic and therapeutic strategies.

Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets

Macrophages are immune cells belonging to the mononuclear phagocyte system. They play crucial roles in immune defense, surveillance, and homeostasis. This review systematically discusses the types of hematopoietic progenitors that give rise to macrophages, including primitive hematopoietic progenitors, erythro-myeloid progenitors, and hematopoietic stem cells. These progenitors have distinct genetic backgrounds and developmental processes. Accordingly, macrophages exhibit complex and diverse functions in the body, including phagocytosis and clearance of cellular debris, antigen presentation, and immune response, regulation of inflammation and cytokine production, tissue remodeling and repair, and multi-level regulatory signaling pathways/crosstalk involved in homeostasis and physiology. Besides, tumor-associated macrophages are a key component of the TME, exhibiting both anti-tumor and pro-tumor properties. Furthermore, the functional status of macrophages is closely linked to the development of various diseases, including cancer, autoimmune disorders, cardiovascular disease, neurodegenerative diseases, metabolic conditions, and trauma. Targeting macrophages has emerged as a promising therapeutic strategy in these contexts. Clinical trials of macrophage-based targeted drugs, macrophage-based immunotherapies, and nanoparticle-based therapy were comprehensively summarized. Potential challenges and future directions in targeting macrophages have also been discussed. Overall, our review highlights the significance of this versatile immune cell in human health and disease, which is expected to inform future research and clinical practice.

Inhibition of sympathetic tone via hypothalamic descending pathway propagates glucocorticoid-induced endothelial impairment and osteonecrosis of the femoral head

Osteonecrosis of the femoral head (ONFH) is a common complication of glucocorticoid (GC) therapy. Recent advances demonstrate that sympathetic nerves regulate bone homeostasis, and GCs lower the sympathetic tone. Here, we show that the dramatically decreased sympathetic tone is closely associated with the pathogenesis of GC-induced ONFH. GCs activate the glucocorticoid receptor (GR) but hinder the activation of the mineralocorticoid receptor (MR) on neurons in the hypothalamic paraventricular nucleus (PVN). This disrupts the balance of corticosteroid receptors (GR/MR) and subsequently reduces the sympathetic outflow in the PVN. Vascular endothelial cells rapidly react to inhibition of sympathetic tone by provoking endothelial apoptosis in adult male mice treated with methylprednisolone (MPS) daily for 3 days, and we find substantially reduced H-type vessels in the femoral heads of MPS-treated ONFH mice. Importantly, treatment with a GR inhibitor (RU486) in the PVN promotes the activation of MR and rebalances the ratio of GR and MR, thus effectively boosting sympathetic outflow, as shown by an increase in tyrosine hydroxylase expression in both the PVN and the sympathetic postganglionic neurons and an increase in norepinephrine levels in both the serum and bone marrow of the femoral head of MPS-treated mice. Rebalancing the corticosteroid receptors mitigates GC-induced endothelial impairment and ONFH and promotes angiogenesis coupled with osteogenesis in the femoral head, while these effects are abolished by chemical sympathectomy with 6-OHDA or adrenergic receptor-β2 (Adrb2) knockout. Furthermore, activating Adrb2 signaling in vivo is sufficient to rescue the GC-induced ONFH phenotype. Mechanistically, norepinephrine increases the expression of the key glycolytic gene 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) via Adrb2-cyclic AMP response element-binding protein (CREB) signaling. Endothelial-specific overexpression of PFKFB3 attenuates endothelial impairment and prevents severe osteonecrosis in MPS-treated Adrb2 knockout mice. Thus, GC inhibits sympathetic tone via the hypothalamic descending pathway, which, in turn, acts as a mediator of GC-induced ONFH.

Pancreatic endocrine and exocrine signaling and crosstalk in physiological and pathological status

The pancreas, an organ with dual functions, regulates blood glucose levels through the endocrine system by secreting hormones such as insulin and glucagon. It also aids digestion through the exocrine system by secreting digestive enzymes. Complex interactions and signaling mechanisms between the endocrine and exocrine functions of the pancreas play a crucial role in maintaining metabolic homeostasis and overall health. Compelling evidence indicates direct and indirect crosstalk between the endocrine and exocrine parts, influencing the development of diseases affecting both. From a developmental perspective, the exocrine and endocrine parts share the same origin—the “tip-trunk” domain. In certain circumstances, pancreatic exocrine cells may transdifferentiate into endocrine-like cells, such as insulin-secreting cells. Additionally, several pancreatic diseases, including pancreatic cancer, pancreatitis, and diabetes, exhibit potential relevance to both endocrine and exocrine functions. Endocrine cells may communicate with exocrine cells directly through cytokines or indirectly by regulating the immune microenvironment. This crosstalk affects the onset and progression of these diseases. This review summarizes the history and milestones of findings related to the exocrine and endocrine pancreas, their embryonic development, phenotypic transformations, signaling roles in health and disease, the endocrine-exocrine crosstalk from the perspective of diseases, and potential therapeutic targets. Elucidating the regulatory mechanisms of pancreatic endocrine and exocrine signaling and provide novel insights for the understanding and treatment of diseases.

Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines

The successful approval of peptide-based drugs can be attributed to a collaborative effort across multiple disciplines. The integration of novel drug design and synthesis techniques, display library technology, delivery systems, bioengineering advancements, and artificial intelligence have significantly expedited the development of groundbreaking peptide-based drugs, effectively addressing the obstacles associated with their character, such as the rapid clearance and degradation, necessitating subcutaneous injection leading to increasing patient discomfort, and ultimately advancing translational research efforts. Peptides are presently employed in the management and diagnosis of a diverse array of medical conditions, such as diabetes mellitus, weight loss, oncology, and rare diseases, and are additionally garnering interest in facilitating targeted drug delivery platforms and the advancement of peptide-based vaccines. This paper provides an overview of the present market and clinical trial progress of peptide-based therapeutics, delivery platforms, and vaccines. It examines the key areas of research in peptide-based drug development through a literature analysis and emphasizes the structural modification principles of peptide-based drugs, as well as the recent advancements in screening, design, and delivery technologies. The accelerated advancement in the development of novel peptide-based therapeutics, including peptide-drug complexes, new peptide-based vaccines, and innovative peptide-based diagnostic reagents, has the potential to promote the era of precise customization of disease therapeutic schedule.

Responses

Your email address will not be published. Required fields are marked *